These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 37210543)

  • 21. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE.
    Panettieri RA; Lugogo N; Moore WC; Chipps BE; Jepson B; Zhou W; Ambrose CS; Genofre E; Carstens DD
    Respir Med; 2023 Sep; 216():107285. PubMed ID: 37290579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
    Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
    J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
    Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
    BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
    Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients.
    Watanabe H; Shirai T; Hirai K; Akamatsu T; Nakayasu H; Tamura K; Masuda T; Takahashi S; Tanaka Y; Kishimoto Y; Oishi K; Saigusa M; Yamamoto A; Morita S; Asada K
    J Asthma; 2022 Sep; 59(9):1796-1804. PubMed ID: 34348060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
    Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
    J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
    Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
    Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
    Pham DN
    J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma.
    Chan R; RuiWen Kuo C; Jabbal S; Lipworth BJ
    J Allergy Clin Immunol; 2023 Mar; 151(3):700-705.e10. PubMed ID: 36400178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of response of severe eosinophilic asthmatic patients to benralizumab.
    Miralles-López JC; Andújar-Espinosa R; Bravo-Gutiérrez FJ; Castilla-Martínez M; Flores-Martín I; Alemany-Francés ML; Pajarón-Fernández MJ; Mora-González A; Cabrejos-Perotti S; El-Molaka Z; Meseguer-Arce J; Avilés-Inglés MJ; Valverde-Molina J; Pérez-Fernández V;
    Allergol Immunopathol (Madr); 2022; 50(6):163-168. PubMed ID: 36335460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
    Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
    Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.